Abstract
Background Along with early onset cancers, multiple primary cancers (MPCs) are likely resulting from increased genetic susceptibility; however, the associated predisposition genes or prevalence of the pathogenic variants genes in MPC patients are often unknown.
Methods We screened 71 patients with MPC of the stomach, colorectal, and endometrium, sequencing 65 cancer predisposition genes. A subset of 19 patients with early onset MPC of stomach and colorectum were further evaluated for at DNA repair and cancer related genes using both normal (germline) and tumor (somatic) whole exome sequencing.
Results Among 71 patients with MPCs, variants predicted to be pathogenic were observed in 15 (21.1%) patients and affected Lynch Syndrome (LS) genes: MLH1 (n=10), MSH6 (n=2), PMS2 (n=2), and MSH2 (n=1). All carriers had tumors with high microsatellite instability and 13 of them (86.7%) were early-onset, consistent with LS. In 19 patients with early-onset MPCs, loss of function (LoF) variants in RECQL5, including a rare East-Asian specific variant, were more prevalent in non-LS MPC than in matched sporadic cancer patients (OR=31.6, p=0.001). Additional evaluation of bi-allelic alterations in the tumor correctly identified LS genes in LS patients and candidates genes in non-LS patients including high-confidence LoF variants in 2 patients, FANCG (c.307+1G>C) and CASP8 (p.R221Sfs*17) both accompanied by somatic loss of heterozygosity in a gastric and a colorectal tumor, respectively.
Conclusions The results suggest that genetic screening should be considered for synchronous cancers and metachronous MPCs of the LS tumor spectrum, particularly in early-onset patients. Susceptibility variants in non-LS genes for MPC patients may exist, but evidence for their role is more elusive than for LS patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study was not registered in any registry including clinicaltrial.gov.
Funding Statement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government. (2017R1D1A1B03032553)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Institutional Review Board (IRB) of Severance Hospital and University of California, San Diego (4-2017-0434, 191543). Patient consent was waived as this study is retrospective design.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset supporting the conclusions of this article is included within the article and its additional file.
Abbreviations
- MPC
- multiple primary cancer
- LS
- Lynch Syndrome
- CPG
- cancer predisposition gene
- LoF
- loss of function
- GC
- gastric cancer
- CRC
- colorectal cancer
- MSI
- microsatellite instability
- MMR
- mismatch repair
- EC
- endometrial cancer
- eoMPC
- early-onset multiple primary cancer
- FFPE
- formalin fixed paraffin embedded
- WES
- whole exome sequencing
- dMMR
- deficiency mismatch repair
- P/LP
- pathogenic or likely pathogenic
- AI
- allelic imbalance
- LOH
- loss of heterozygosity
- TCGA
- the cancer genome atlas
- MAF
- minor allele frequency
